Faruqi & Faruqi Investigates Skye Bioscience Claims on Behalf of Investors

Investor Alert: Faruqi & Faruqi Investigates Skye Bioscience

Faruqi & Faruqi, LLP, a prominent firm specializing in securities law, is currently looking into potential claims on behalf of investors who have suffered losses in Skye Biosciences, Inc. The investigation focuses on whether Skye and its executives violated federal securities laws by making misleading statements regarding the effectiveness of their product, nimacimab.

Background on Skye Biosciences

Skye Biosciences, publicly traded under the ticker NASDAQ: SKYE, has garnered attention from investors for its innovative approach to cannabinoid therapies. However, the recent developments regarding nimacimab have raised significant concerns. On October 6, 2025, Skye announced disappointing results from its Phase 2a clinical trial of nimacimab, which was intended to demonstrate its effectiveness as a weight loss aid.

The trial's findings showed that the drug did not meet its primary endpoint compared to a placebo, which has led to a dramatic 60% drop in the company's stock price, from $4.75 to $1.90 per share, indicating that investor confidence has waned significantly.

Allegations Against Skye Bioscience

The allegations suggest that Skye and its leadership may have overstated the drug's efficacy and market potential. Specifically, there are claims that:
1. Nimacimab was not as effective as previously claimed, potentially misleading investors.
2. The company's public statements regarding the drug's clinical and commercial prospects were materially false and misleading.
3. Skye failed to disclose critical data that would have influenced investors' decisions.

According to Faruq & Faruqi, investors who purchased Skye securities between November 4, 2024, and October 3, 2025, should be aware of their rights and the impending class action lawsuit. The deadline to seek lead plaintiff status is January 16, 2026, prompting a call for affected investors to come forward.

How to Get Involved

Investors who believe they have suffered losses due to the alleged misconduct are advised to contact Faruqi & Faruqi partner James (Josh) Wilson. He can be reached directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm is encouraging any investor with additional information about Skye's practices, including former employees or whistleblowers, to reach out.

Faruqi & Faruqi has a strong track record, having recovered hundreds of millions for investors since its establishment in 1995. The firm is committed to protecting the rights of investors who may have been misled.

Conclusion

The situation surrounding Skye Biosciences serves as a reminder to all investors to remain vigilant in their investments and be aware of potential legal actions that can affect their financial interests. With the deadline approaching for seeking lead plaintiff status, affected investors are urged to engage promptly. For ongoing updates, investors can follow Faruqi & Faruqi on their official platforms.

This development in the biopharmaceutical sector raises essential questions regarding corporate responsibility and transparency. Investors are advised to stay informed and consider their options carefully as this case progresses.